CompletedEarly Phase 1NCT05361083

First-in-human Evaluation of [18F]CETO

Studying Adrenal Cushing syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Uppsala University
Principal Investigator
Per Hellman, Professor
Uppsala University and Uppsala University Hospital
Intervention
F18CETO(drug)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20192022

Study locations (1)

Collaborators

Uppsala University Hospital · British Medical Research Council

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05361083 on ClinicalTrials.gov

Other trials for Adrenal Cushing syndrome

Additional recruiting or active studies for the same condition.

See all trials for Adrenal Cushing syndrome

← Back to all trials